Epanova® for Lowering Very High Triglycerides (EVOLVE)

AstraZeneca

Status and phase: Completed; Phase 3; Phase 2

Conditions: Severe Hypertriglyceridemia

Treatments: Drug: omefas; Drug: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01242527

OM-EPA-003

Details and patient eligibility

About

The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.

Enrollment: 399 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men or women, >=18 years of age.
• Very high serum TG values in the range >=500 mg/dL and <2000 mg/dL (>=5.65 mmol/L and <22.60 mmol/L)

Exclusion criteria

• Allergy or intolerance to omega-3 fatty acids, omega-3-acid ethyl esters, or fish.
• Known lipoprotein lipase impairment or deficiency or apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.
• Unable to discontinue use of omega-3 drugs/supplements.
• Unable to discontinue use of bile acid sequestrants, fibrates or niacin (other than niacin-containing vitamins <200 mg), or any supplement used to alter lipid metabolism.
• Women who are pregnant, lactating, or planning to become pregnant. Women of childbearing potential who are not using acceptable contraceptive methods.
• Use of tamoxifen, estrogens or progestins that has not been stable for >4 weeks prior to Visit 1.
• Use of oral or injected corticosteroids or anabolic steroids.
• History of pancreatitis.
• History of symptomatic gallstone disease, unless treated with cholecystectomy.
• Uncontrolled diabetes.
• Uncontrolled hypothyroidism or thyroid stimulating hormone (TSH).
• History of cancer (other than basal cell carcinoma) in the past 2 years.
• Cardiovascular event (i.e., myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient ischemic attack, unstable congestive heart failure requiring a change in treatment) or revascularization procedure within six months prior to Visit 1.
• Use of anticoagulants (e.g. warfarin [Coumadin®], coumarin, heparin, enoxaparin, clopidogrel).
• Presence of an aortic aneurysm or resection of an aortic aneurysm within six months prior to Visit 1.
• Recent history (within six months prior to Visit 1) or current significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal or immunologic disease.
• Poorly controlled hypertension.
• Any of the following laboratory criteria: serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST), glucose, glomerular filtration rate (GFR), platelet count,or hemoglobin outside of study range.
• Recent history (past 12 months) of drug abuse or alcohol abuse.
• Exposure to any investigational product, within 4 weeks prior to Visit 1.
• Presence of any other condition the Investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

399 participants in 4 patient groups, including a placebo group

placebo

Placebo Comparator group

Treatment:

Drug: placebo

Epanova 2 g

Experimental group

Treatment:

Drug: omefas

Drug: omefas

Drug: omefas

Epanova 3 g

Experimental group

Treatment:

Drug: omefas

Drug: omefas

Drug: omefas

Epanova 4 g

Experimental group

Treatment:

Drug: omefas

Drug: omefas

Drug: omefas